Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology's stages

Introduction Many drugs used to combat schistosomiasis, Chagas disease, and leishmaniasis (SCL) have clinical limitations such as: high toxicity to the liver, kidneys and spleen; reproductive, gastrointestinal, and heart disorders; teratogenicity. In this sense, drug delivery systems (DDSs) have been described in the literature as a viable option for overcoming the limitations of these drugs. An analysis of the level of development (TRL) of patents can help in determine the steps that must be taken for promising technologies to reach the market. Areas covered This study aimed to analyze the stage of development of DDSs for the treatment of SCL described in patents. In addition, we try to understand the main reasons why many DDSs do not reach the market. In this study, we examined DDSs for drugs indicated by WHO and treatment of SCL, by performing a search for patents. Expert opinion In this present work we provide arguments that support the hypothesis that there is a lack of integration between academia and industry to finance and continue research, especially the development of clinical studies. We cite the translational research consortia as the potential alternative for developing DDSs to combat NTDs.

Automated summary

Many drugs used to combat Schistosomiasis, Chagas disease, and Leishmaniasis have clinical limitations, but drug delivery systems (DDSs) are seen as a viable option to overcome these limitations. Analyzing the level of development of DDS patents can help determine the necessary steps for technologies to reach the market. Lack of integration between academia and industry for funding and continued research is identified as a barrier for the development of DDSs for neglected tropical diseases.